Project Navigator
Let's try to finance it!
A new, user friendly way, to get information about current clinical trials available to prostate cancer patients.
Tags
177Lu-PSMA-617 abiraterone acetate ADC ADT AI ai in healthcare antibody-drug conjugate apalutamide ATM B7-H3 bispecific antibody bone metastases bone metastasis BRCA cancer immunotherapy CAR-T clinical trial clinical trials crispr darolutamide docetaxel drug repurposing drug resistance enzalutamide EZH2 inhibitor HRR immunotherapy mcrpc metastatic castration-resistant prostate cancer metastatic hormone-sensitive prostate cancer mHSPC mRNA NEPC neuroendocrine prostate cancer olaparib oncolytic virus Pluvicto prostate cancer protac PSMA radioligand therapy radiopharmaceuticals real-world data T-cell therapy theranostics
Latest Posts
- GSK5764227: An Antibody-Drug Conjugate Targeting B7-H3 Enters Phase 1/2 Trial December 12, 2025
- MHB048C: A New PSMA-Targeted Therapy for Advanced Solid Tumors December 12, 2025
- Logic-gated DARPins, a Promising Advancement in Immune Therapy for Solid Tumors December 11, 2025
- CONVERT‑HB1: a Phase 2 Trial About Prostate Directed Treatment After Systemic Treatment in mHSPC December 11, 2025
CAN-2409 Shows Promise in Prostate Cancer Treatment
/in Clinical Trial, Localized/by MaxSequencing Radium-223 and Lutetium-177 PSMA Therapy in mCRPC Management: Insights from the RaLu Trial
/in Clinical Trial, Metastatic, Phase 1/by MaxB7-H4-Targeting Antibody-Drug Conjugate, LNCB74, Gets Green Light for Clinical Trials for Solid Tumors
/in Clinical Trial, Phase 1/by MaxOP-3136: New Drug Receives FDA Clearance to Begin Clinical Trials
/in Clinical Trial, Metastatic, Phase 1/by MaxA New Dawn for Disease Treatment: Combining mRNA and RNAi Therapies
/in CRISPR, Preclinical Research/by MaxMatching-Adjusted Comparison of PARPi Therapies for mCRPC: Talazoparib + Enzalutamide Wins
/in Clinical Trial, Metastatic, Observational, Post-hoc, Retrospective studies/by MaxMapping the Gut: A New Atlas Illuminates the Path to Understanding and Treating Cancer (and other diseases)
/in Not PCa related, Preclinical Research/by MaxPreclinical: A More Efficient and Selective Path to Anti-Cancer Drugs
/in Preclinical Research/by Max